Endologix, Inc. (ELGX) Receives Average Recommendation of “Hold” from Analysts

Share on StockTwits

Endologix, Inc. (NASDAQ:ELGX) has earned a consensus rating of “Hold” from the nine research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $4.75.

Several analysts have weighed in on the stock. ValuEngine raised shares of Endologix from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. BidaskClub raised shares of Endologix from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 24th. Stifel Nicolaus boosted their target price on shares of Endologix from $4.50 to $5.00 and gave the stock a “hold” rating in a research report on Monday, May 21st. Zacks Investment Research raised shares of Endologix from a “sell” rating to a “hold” rating in a research report on Monday, May 7th. Finally, Oppenheimer set a $5.00 target price on shares of Endologix and gave the stock a “hold” rating in a research report on Thursday, May 3rd.

NASDAQ:ELGX traded up $0.11 during trading hours on Monday, hitting $5.86. 1,246,125 shares of the company were exchanged, compared to its average volume of 621,890. The company has a market cap of $483.06 million, a PE ratio of -12.21 and a beta of 0.44. Endologix has a 52-week low of $3.75 and a 52-week high of $6.72. The company has a current ratio of 2.13, a quick ratio of 1.37 and a debt-to-equity ratio of 3.58.

Endologix (NASDAQ:ELGX) last released its earnings results on Wednesday, May 2nd. The medical instruments supplier reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.03. The company had revenue of $42.28 million for the quarter, compared to the consensus estimate of $41.14 million. Endologix had a negative net margin of 35.86% and a negative return on equity of 47.01%. Endologix’s revenue was down .8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.18) EPS. analysts expect that Endologix will post -0.7 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Altrinsic Global Advisors LLC boosted its holdings in shares of Endologix by 9.5% in the 1st quarter. Altrinsic Global Advisors LLC now owns 1,035,000 shares of the medical instruments supplier’s stock valued at $4,378,000 after acquiring an additional 90,000 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Endologix by 8.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 380,648 shares of the medical instruments supplier’s stock valued at $1,611,000 after acquiring an additional 30,585 shares during the last quarter. Lake Street Advisors Group LLC purchased a new stake in shares of Endologix in the 4th quarter valued at $120,000. MetLife Investment Advisors LLC purchased a new stake in shares of Endologix in the 4th quarter valued at $236,000. Finally, Deutsche Bank AG boosted its holdings in shares of Endologix by 111.7% in the 4th quarter. Deutsche Bank AG now owns 190,868 shares of the medical instruments supplier’s stock valued at $1,019,000 after acquiring an additional 100,703 shares during the last quarter. 97.11% of the stock is currently owned by institutional investors and hedge funds.

About Endologix

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Symantec  Price Target Increased to $20.00 by Analysts at Deutsche Bank
Symantec Price Target Increased to $20.00 by Analysts at Deutsche Bank
Barrington Research Lowers Lions Gate Entertainment Corp. Class A  Price Target to $27.00
Barrington Research Lowers Lions Gate Entertainment Corp. Class A Price Target to $27.00
News Corp Class A  Upgraded to “Hold” at Zacks Investment Research
News Corp Class A Upgraded to “Hold” at Zacks Investment Research
Covia  Receives “Buy” Rating from Jefferies Financial Group
Covia Receives “Buy” Rating from Jefferies Financial Group
$0.50 EPS Expected for Government Properties Income Trust  This Quarter
$0.50 EPS Expected for Government Properties Income Trust This Quarter
Paragon  Price Hits $0.0702 on Top Exchanges
Paragon Price Hits $0.0702 on Top Exchanges


© 2006-2018 Ticker Report. Google+.